LSTAHealthcare · BiotechnologyThe 2 Wall Street analysts covering Lisata Therapeutics, Inc. hold a median 12-month price target of $4 — +270.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 12 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Lisata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Value (16): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LSTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +270.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 21 Jan 2026 | Brookline Capital | Downgrade | Hold | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 July 2025 | Brookline Capital | Maintains | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Jan 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Oct 2022 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LSTA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Lisata Therapeutics, Inc. returned −55.6% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 4% of US stocks
Cheaper than 67% of US stocks
Cheaper than 61% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lisata Therapeutics, Inc. has a market value of $11.5M and an enterprise value of −$1.1M.
Revenue in the twelve months to 30 June 2026: $100K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$14.6M, a −14621.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$12.3M.
Trailing P/E: −0.5×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lisata Therapeutics, Inc. employs 21 people — $5K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lisata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lisata Therapeutics said the US Patent and Trademark Office granted it a Method of Use patent covering experimental drug certepetide for treating pancreatic cancer and other solid tumors.
Why it matters — The patent grant is relevant to LSTA watchers tracking intellectual-property developments around certepetide and its potential uses.
Lisata Therapeutics announced that the USPTO granted a new method-of-use patent for certepetide in the treatment of pancreatic cancer and other solid tumors.
Why it matters — The patent grant adds intellectual-property coverage for the company's certepetide program in these cancer indications.
Lisata Therapeutics subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002, a first-in-class antibody therapy being developed for acromegaly, a rare endocrine disorder. Marea is focused on developing medicines for cardioendocrine diseases.
Why it matters — This marks a key clinical development milestone for Lisata's subsidiary and advances MAR002 as a potential new treatment option for a rare endocrine disorder.
Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced that the first patient has been dosed in a Phase 2 clinical trial of MAR002, an investigational therapy for acromegaly. The trial follows promising Phase 1 results showing deep and durable IGF-1 suppression, with pharmacokinetic properties that may allow dosing as infrequently as every two weeks.
Why it matters — The advancement of MAR002 into Phase 2 suggests progress in Lisata's pipeline, with a potential dosing advantage over the current daily-injection standard of care for acromegaly.
Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced that data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an experimental antibody targeting the protein ANGPTL4, intended to lower triglycerides and improve fat handling.
Why it matters — A late-breaking presentation slot at a major scientific conference highlights the clinical significance and visibility of Lisata's lead candidate MAR001, a key development-stage asset for the company.
The 2 Wall Street analysts covering Lisata Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Lisata Therapeutics, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lisata Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Lisata Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +270.4% from the last close, and Ticker Nerd's factor model ranks Lisata Therapeutics, Inc. 56 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lisata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LSTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
Lisata Therapeutics, Inc. returned -55.6% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases.
The most recent item we track (Proactive Investors, 8 Oct 2026): "Lisata Therapeutics wins new US patent for pancreatic cancer drug". Lisata Therapeutics said the US Patent and Trademark Office granted it a Method of Use patent covering experimental drug certepetide for treating pancreatic cancer and other solid tumors.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is designed to activate a novel uptake pathway that may improve the delivery and penetration of anti-cancer drugs within solid tumors. Lisata Therapeutics’ current work centers on oncology programs that evaluate certepetide in combination with existing cancer regimens across several solid tumor settings. The company also maintains research efforts in other disease areas through its broader development pipeline. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics plays a role in the biopharmaceutical market by advancing treatment approaches intended to enhance how established therapies reach tumor tissue.
CEO Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. · 21 employees · United States · https://www.lisata.com
